JP2014533949A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014533949A5 JP2014533949A5 JP2014541330A JP2014541330A JP2014533949A5 JP 2014533949 A5 JP2014533949 A5 JP 2014533949A5 JP 2014541330 A JP2014541330 A JP 2014541330A JP 2014541330 A JP2014541330 A JP 2014541330A JP 2014533949 A5 JP2014533949 A5 JP 2014533949A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- subject
- seq
- acid sequence
- unc5c
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 33
- 238000000034 method Methods 0.000 claims 28
- 238000006467 substitution reaction Methods 0.000 claims 18
- 208000024827 Alzheimer disease Diseases 0.000 claims 16
- 108090000623 proteins and genes Proteins 0.000 claims 15
- 108700028369 Alleles Proteins 0.000 claims 13
- 230000007614 genetic variation Effects 0.000 claims 13
- 239000003153 chemical reaction reagent Substances 0.000 claims 12
- 101000841744 Homo sapiens Netrin receptor UNC5C Proteins 0.000 claims 11
- 102100029514 Netrin receptor UNC5C Human genes 0.000 claims 11
- 239000000523 sample Substances 0.000 claims 11
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims 10
- 101000996663 Homo sapiens Neurotrophin-4 Proteins 0.000 claims 10
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 10
- 102100033857 Neurotrophin-4 Human genes 0.000 claims 10
- 238000001514 detection method Methods 0.000 claims 8
- 108091034117 Oligonucleotide Proteins 0.000 claims 6
- 230000002068 genetic effect Effects 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 239000003550 marker Substances 0.000 claims 4
- 238000003745 diagnosis Methods 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 238000012163 sequencing technique Methods 0.000 claims 2
- 238000012360 testing method Methods 0.000 claims 2
- 101150037123 APOE gene Proteins 0.000 claims 1
- 102100029470 Apolipoprotein E Human genes 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 239000003298 DNA probe Substances 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 108020004518 RNA Probes Proteins 0.000 claims 1
- 239000003391 RNA probe Substances 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- -1 cerebrospinal fluid Substances 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 102000054766 genetic haplotypes Human genes 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 230000006996 mental state Effects 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 102000054765 polymorphisms of proteins Human genes 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 238000007790 scraping Methods 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 210000000582 semen Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 210000004243 sweat Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161558197P | 2011-11-10 | 2011-11-10 | |
| US61/558,197 | 2011-11-10 | ||
| US201261671531P | 2012-07-13 | 2012-07-13 | |
| US61/671,531 | 2012-07-13 | ||
| PCT/US2012/064466 WO2013071119A2 (en) | 2011-11-10 | 2012-11-09 | Methods for treating, diagnosing and monitoring alzheimer's disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018090050A Division JP2018166507A (ja) | 2011-11-10 | 2018-05-08 | アルツハイマー病を治療、診断、および監視するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014533949A JP2014533949A (ja) | 2014-12-18 |
| JP2014533949A5 true JP2014533949A5 (OSRAM) | 2016-01-07 |
| JP6338530B2 JP6338530B2 (ja) | 2018-06-06 |
Family
ID=47222323
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541330A Expired - Fee Related JP6338530B2 (ja) | 2011-11-10 | 2012-11-09 | アルツハイマー病を治療、診断、および監視するための方法 |
| JP2018090050A Pending JP2018166507A (ja) | 2011-11-10 | 2018-05-08 | アルツハイマー病を治療、診断、および監視するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018090050A Pending JP2018166507A (ja) | 2011-11-10 | 2018-05-08 | アルツハイマー病を治療、診断、および監視するための方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140371094A1 (OSRAM) |
| EP (1) | EP2776582A2 (OSRAM) |
| JP (2) | JP6338530B2 (OSRAM) |
| KR (1) | KR20140089384A (OSRAM) |
| CN (3) | CN106011243A (OSRAM) |
| AR (1) | AR088827A1 (OSRAM) |
| BR (1) | BR112014011127A2 (OSRAM) |
| CA (1) | CA2854779A1 (OSRAM) |
| HK (1) | HK1214631A1 (OSRAM) |
| MX (1) | MX2014005683A (OSRAM) |
| RU (1) | RU2014123511A (OSRAM) |
| WO (1) | WO2013071119A2 (OSRAM) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7702468B2 (en) | 2006-05-03 | 2010-04-20 | Population Diagnostics, Inc. | Evaluating genetic disorders |
| US10522240B2 (en) | 2006-05-03 | 2019-12-31 | Population Bio, Inc. | Evaluating genetic disorders |
| EP2601609B1 (en) | 2010-08-02 | 2017-05-17 | Population Bio, Inc. | Compositions and methods for discovery of causative mutations in genetic disorders |
| EP2766483B1 (en) | 2011-10-10 | 2022-03-23 | The Hospital For Sick Children | Methods and compositions for screening and treating developmental disorders |
| EP2773779B1 (en) * | 2011-11-04 | 2020-10-14 | Population Bio, Inc. | Methods and compositions for diagnosing, prognosing, and treating neurological conditions |
| WO2013120018A1 (en) | 2012-02-09 | 2013-08-15 | Population Diagnostics, Inc. | Methods and compositions for screening and treating developmental disorders |
| DK2895621T3 (da) | 2012-09-14 | 2020-11-30 | Population Bio Inc | Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande |
| EP2900835B1 (en) | 2012-09-27 | 2025-04-30 | Population Bio, Inc. | Method for screening and treating developmental disorders |
| US11089959B2 (en) | 2013-03-15 | 2021-08-17 | I2Dx, Inc. | Electronic delivery of information in personalized medicine |
| US9782075B2 (en) | 2013-03-15 | 2017-10-10 | I2Dx, Inc. | Electronic delivery of information in personalized medicine |
| WO2015082721A1 (en) * | 2013-12-06 | 2015-06-11 | Life & Brain Gmbh | MEANS AND METHODS FOR ESTABLISHING A CLINICAL PROGNOSIS OF DISEASES ASSOCIATED WITH THE FORMATION OF AGGREGATES OF Aβ1-42 |
| US10724096B2 (en) | 2014-09-05 | 2020-07-28 | Population Bio, Inc. | Methods and compositions for inhibiting and treating neurological conditions |
| DK3201317T3 (da) * | 2014-09-30 | 2020-01-20 | Bgi Shenzhen | Biomarkører for rheumatoid arthritis og anvendelse deraf |
| US11756655B2 (en) * | 2015-10-09 | 2023-09-12 | Guardant Health, Inc. | Population based treatment recommender using cell free DNA |
| JP2017189121A (ja) * | 2016-04-11 | 2017-10-19 | 国立大学法人旭川医科大学 | 抗ＴＮＦα抗体適応疾患の治療における抗ＴＮＦα抗体投与時反応の発症リスクを判定する方法、並びに該判定用オリゴヌクレオチドキット |
| KR102024862B1 (ko) * | 2016-10-19 | 2019-09-25 | 삼성디스플레이 주식회사 | 표시 장치 |
| US11725232B2 (en) | 2016-10-31 | 2023-08-15 | The Hong Kong University Of Science And Technology | Compositions, methods and kits for detection of genetic variants for alzheimer's disease |
| US10240205B2 (en) | 2017-02-03 | 2019-03-26 | Population Bio, Inc. | Methods for assessing risk of developing a viral disease using a genetic test |
| WO2018212427A1 (ko) * | 2017-05-15 | 2018-11-22 | 조선대학교산학협력단 | 알츠하이머병 위험도와 관련된 apoe 프로모터 단일염기변이 및 이것의 용도 |
| JP7112660B2 (ja) * | 2018-03-13 | 2022-08-04 | アイ２ディーエックス インコーポレイテッド | 個別化医療における情報の電子配信 |
| CN108753954B (zh) * | 2018-06-26 | 2022-11-18 | 中南大学湘雅医院 | 痴呆相关基因的捕获探针组、试剂盒、文库构建方法和用途 |
| CA3108807A1 (en) | 2018-08-08 | 2020-02-13 | Pml Screening, Llc | Methods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing |
| WO2020143044A1 (zh) * | 2019-01-11 | 2020-07-16 | 深圳市双科生物科技有限公司 | 一种双质控检测方法 |
| KR20200130165A (ko) * | 2019-05-10 | 2020-11-18 | 주식회사 엠제이브레인바이오 | Top3b 유전자 변이 기반 치매 진단방법 |
| WO2021037027A1 (en) * | 2019-08-29 | 2021-03-04 | The Hong Kong University Of Science And Technology | Genetic variants for diagnosis of alzheimer's disease |
| GB202004832D0 (en) * | 2020-04-01 | 2020-05-13 | Instituto De Medicina Molecular Faculdade De Medicina Univ De Lisboa | Therapeutic agaents, pharmaceutical compositions, and associated biomarkers |
| KR102561438B1 (ko) * | 2020-11-04 | 2023-07-28 | 사회복지법인 삼성생명공익재단 | 뇌 아밀로이드 베타 축적 가능성을 예측하는 방법 |
| CN112980954B (zh) * | 2021-03-03 | 2022-02-25 | 首都医科大学宣武医院 | 一种预测神经退行性疾病风险的试剂盒及其用途 |
| EP4649090A1 (en) * | 2023-01-09 | 2025-11-19 | Eli Lilly And Company | Anti-unc5c antibodies |
| CN117230184B (zh) * | 2023-11-13 | 2024-03-19 | 深圳康美生物科技股份有限公司 | 基于飞行时间核酸质谱技术检测阿尔兹海默病基因的核酸组合及应用 |
| WO2025125898A1 (en) * | 2023-12-15 | 2025-06-19 | Alchemab Therapeutics Ltd | Anti-unc5c antibodies and uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US4683203A (en) | 1984-04-14 | 1987-07-28 | Redco N.V. | Immobilized enzymes, processes for preparing same, and use thereof |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| IE61148B1 (en) | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| ATE191853T1 (de) | 1992-07-27 | 2000-05-15 | Us Health | Zielgerichte liposome zur blut-hirne schranke |
| US5498531A (en) | 1993-09-10 | 1996-03-12 | President And Fellows Of Harvard College | Intron-mediated recombinant techniques and reagents |
| EP2369007B1 (en) | 1996-05-29 | 2015-07-29 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
| EP1313880A2 (en) | 2000-05-30 | 2003-05-28 | PE Corporation (NY) | Methods for detecting target nucleic acids using coupled ligation and amplification |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| US20030083299A1 (en) | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| US20030119004A1 (en) | 2001-12-05 | 2003-06-26 | Wenz H. Michael | Methods for quantitating nucleic acids using coupled ligation and amplification |
| KR101186210B1 (ko) | 2002-12-03 | 2012-10-08 | 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 | 혈뇌장벽을 통과하는 물질 수송용 인공 저밀도 지단백질 운반체 |
| PT2282779E (pt) * | 2008-04-29 | 2013-05-28 | Pharnext | Novas abordagens terapêuticas para o tratamento da doença de alzheimer e doenças relacionadas através de uma modulação de resposta ao stresse celular |
| CN101812525A (zh) * | 2010-04-09 | 2010-08-25 | 南通大学 | 与ad发病相关的基因网络通路分析模型的建立方法 |
-
2012
- 2012-11-09 CN CN201610369743.5A patent/CN106011243A/zh active Pending
- 2012-11-09 CN CN201510445488.3A patent/CN105063186A/zh active Pending
- 2012-11-09 CA CA2854779A patent/CA2854779A1/en not_active Abandoned
- 2012-11-09 WO PCT/US2012/064466 patent/WO2013071119A2/en not_active Ceased
- 2012-11-09 EP EP12791045.3A patent/EP2776582A2/en not_active Withdrawn
- 2012-11-09 BR BR112014011127A patent/BR112014011127A2/pt not_active IP Right Cessation
- 2012-11-09 RU RU2014123511/10A patent/RU2014123511A/ru unknown
- 2012-11-09 CN CN201280055180.2A patent/CN103930568A/zh active Pending
- 2012-11-09 US US14/357,192 patent/US20140371094A1/en not_active Abandoned
- 2012-11-09 JP JP2014541330A patent/JP6338530B2/ja not_active Expired - Fee Related
- 2012-11-09 MX MX2014005683A patent/MX2014005683A/es unknown
- 2012-11-09 KR KR1020147014033A patent/KR20140089384A/ko not_active Withdrawn
- 2012-11-09 AR ARP120104237A patent/AR088827A1/es unknown
-
2014
- 2014-08-06 HK HK16102579.7A patent/HK1214631A1/zh unknown
-
2018
- 2018-05-08 JP JP2018090050A patent/JP2018166507A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014533949A5 (OSRAM) | ||
| CN111032881B (zh) | 核酸的精确和大规模平行定量 | |
| RU2014123511A (ru) | Способы лечения, диагностики и мониторинга болезни альцгеймера | |
| CN107475371B (zh) | 发现药物基因组生物标志物的方法 | |
| JP2008526249A5 (OSRAM) | ||
| JP2012503985A5 (OSRAM) | ||
| JP2011528903A5 (OSRAM) | ||
| JP2010520745A5 (OSRAM) | ||
| JP5663491B2 (ja) | 標的核酸の検出方法 | |
| JP2010533477A5 (OSRAM) | ||
| JP2010528590A5 (OSRAM) | ||
| CN104017908A (zh) | 人乳头状瘤病毒的快速基因型鉴定分析及其装置 | |
| KR20110094041A (ko) | 정상 안압 녹내장 질환 감수성 유전자 및 그 이용 | |
| JP2009523411A5 (OSRAM) | ||
| JP2013074888A (ja) | ＩＬ２８Ｂ（ｒｓ８０９９９１７）とＩＴＰＡ（ｒｓ１１２７３５４）の変異を検出する方法 | |
| CN104293968B (zh) | 一组用于检测非综合征性唇腭裂遗传易感性的多态性位点及检测试剂盒 | |
| KR101761801B1 (ko) | 코 표현형 판단용 조성물 | |
| WO2005038427A2 (en) | Rapid identification of viruses of the upper respiratory tract infection including sars causing coronus viruses | |
| JP5322471B2 (ja) | メチル化ｄｎａの解析方法及びプライマーセット | |
| EP3315613B1 (en) | Methods and kits for diagnosing or assessing the risk of cervical cancer | |
| TWI579722B (zh) | 藥物不良反應風險評估方法及其裝置 | |
| JP6494356B2 (ja) | 非アルコール性脂肪性肝疾患及び／又は非アルコール性脂肪肝炎の発症リスク及び／又は重症化リスクの判定方法、並びに該判定用オリゴヌクレオチドキット | |
| WO2012056694A1 (ja) | 乳がん発症感受性の判定方法 | |
| EP4460581A1 (en) | Assay device, method for determining genetic predisposition to severe forms of sars-cov2 infection | |
| KR102268059B1 (ko) | 운동 민감도 예측용 조성물, 키트, 및 이를 이용한 방법 |